Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of norucholic acid in primary sclerosing cholangitis
2024-514292-18-00Phase 3Authorised
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, open-label, single-arm trial of norursodeoxycholic acid in Primary Sclerosing Cholangitis (PSC), sponsored by Dr. Falk Pharma GmbH. Primary endpoints: Occurrence of treatment-emergent adverse events, Occurrence of serious treatment-emergent adverse events and 4 more. Planned start Mar 2025; status: authorised.
02
Drugs
norursodeoxycholic acid
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on 2024-514292-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514292-18-00.